Local research. Human connections. WCR Miami Lakes (786) 483-7856
Back to study searchNCT06842446
RecruitingNCT06842446ClinicalTrials.gov record

Systematic Machine Learning Algorithm for Rapid Thrombosis Detection

Deep Vein Thrombosis

THE QUICK READ

What this study involves

The registry says this study is recruiting. Individual locations may have different availability.

Study type
Interventional
Phase
Not applicable
Age range
18 years - Not specified
Sex eligible
All sexes
Healthy volunteers
Not accepted
Participants
1000 Estimated

These are starting points, not an eligibility decision. The research team must review the full requirements.

About the research

The goal of this clinical trial is to compare the use of a machine learning-based algorithm and point-of-care D-dimer to laboratory D-dimer and compression ultrasound to exclude deep vein thrombosis in the under extremities in patients referred to a medical department suspected of having deep vein thrombosis. The main aim is to answer are if a machine learning algorithm and point of care D-dimer can exclude deep vein thrombosis in more patients than clinical assessment and D-dimer alone.

Read the full description

All participants will follow the usual diagnostic algorithm used for patients with suspected DVT referred to Ostfold Hospital (all patients are examined by a physician, D-dimer is analyzed in all patients, ultrasound is performed by a radiologist in patients with positive D-dimer). In addition to usual care, POC D-dimer, POC ultrasound (performed by ED physicians), blood sampling for biobanking, and photographies of the under extremities will be performed. The machine learning model will be tested to see if the prediction is correct. In participants where ultrasound is performed, it will also be assessed whether the machine learning algorithm could have excluded the participant without the use of ultrasound. None of the additional procedures will have any impact on the patient diagnostics or treatment.

Who may be able to participate?

The list below is the sponsor’s full registry wording. It can include conditions, prior treatment, test results and other requirements. A match in search does not mean you qualify.

Inclusion Criteria:

  • Patients referred to the ED due to suspicion of DVT
  • Age ≥ 18 years
  • Able to give informed consent

Exclusion Criteria:

  • Ongoing use of anticoagulation for more than 72 hours
  • Previous participation in the study
  • Life expectancy of less than three months.
Understand screening

Treatment, groups and participation

The registry may describe treatments and study duration without a complete visit calendar. Ask the study team for the exact schedule, procedures, risks, costs and alternatives. Keep your usual care plan unless your treating clinician tells you otherwise.

Assignment
Not applicable
Masking
No masking
All participants

All participants will be treated the same way.

Diagnostic Test: POC D-dimer · Diagnostic Test: POC ultrasound · Diagnostic Test: Machine learning model

POC D-dimer DIAGNOSTIC_TEST

POC D-dimer will be compared to laboratory D-dimer in hospital setting and used in a machine learning model

POC ultrasound DIAGNOSTIC_TEST

Point of care (POC) ultrasound performed by ED physicians compared to ultrasound performed by radiologist. POC ultrasound 3 point examination performed by ED physician will be compared with POC ultrasound full leg examination performed by ED physician.

Machine learning model DIAGNOSTIC_TEST

The DSS will be compared to the usual strategy. It will also be estimated how many participants where DVT could have been excluded without ultrasound.

Prepare your questions

What researchers are measuring

Outcome measures describe what is being studied. They are not proof that a treatment works.

Primary measures

Safety of the new strategy (POC D-dimer, ML-based prediction model, POC CUS by emergency physician)

Time frame: From enrollment to the end of the primary assessment period (90 days)

Evaluate the safety of a new strategy consisting of POC D-dimer and an ML-based prediction model followed by CUS performed by emergency physicians by comparing the new strategy's safety with our standard care by measuring the proportion of patients in whom DVT is excluded according to the new strategy but was diagnosed with DVT by standard care or in whom DVT is diagnosed within the 90-day follow up.

Secondary measures

Evaluate the efficiency of the new strategy

Time frame: From enrollment to the end of the primary assessment period (90 days)

The proportion of patients in whom DVT can be ruled out by the ML-based prediction model with POC D-dimer compared to the efficiency of Wells score and laboratory D-dimer

Validate the safety and efficiency of the ML-based prediction model

Time frame: From enrollment to the end of the primary assessment period (90 days)

Safety will be determined by the proportion of patients in whom DVT is excluded by the ML-model but diagnosed by standard care. Efficiency will be determined by the proportion of patients in whom DVT can be excluded by the ML-based model

Evaluate concordance between CUS performed by emergency physicians and radiologists.

Time frame: From time of enrollment until time of ultrasound examination performed by radiologist, assessed up to 48 hours.

Determine the proportion of false negative and false positive diagnosis of DVT in emergency physician-performed ultrasound compared with ultrasound performed by radiologists.

Evaluate concordance between POC D-dimers in an ED setting and laboratory D-dimers.

Time frame: From enrollment to the completion of D-dimer analysis, assessed up to 24 hours.

Compare the two POC D-dimers with the STA-Liatest D-dimer and Siemens INNOVANCE by direct comparison of the true/false positive/negative results.

Evaluate the hypothetical time to be completed for the novel strategy compared to the standard strategy.

Time frame: From time of enrollment until time of discharge from the emergency department either discharged from the hospital or hospitalized, assessed up to 24 hours.

Estimating the total management time defined as time from ED registration to ED discharge in patients evaluated according to the new strategy compared to standard care.

Evaluate the safety of a limited ultrasound protocol (two-point and proximal) compared to full-leg CUS performed by emergency physicians and radiologists

Time frame: 90 days after enrollment.

Estimating the proportion of patients in whom DVT was ruled out by the limited ultrasound protocol but was diagnosed with DVT by the whole-leg ultrasound.

No results are flagged as posted.

Review the complete result tables and limitations in the official record.

Open official results ↗

Research locations (1)

The overall study status and a local site’s status can differ. Confirm that location’s availability before traveling.

1 locations

Østfold Hospital TrustSarpsborg, NorwayRecruiting
Hans J Myklebust-Hansen, M.D.CONTACThansjoakim_mh@outlook.com004797501765
Hans J Myklebust-Hansen, M.D.SUB_INVESTIGATOR
View location on map ↗

Study team and timeline

Lead sponsor
Ostfold Hospital Trust
Study start
Jan 6, 2025 Actual
Primary completion
Apr 5, 2027 Estimated
Study completion
Apr 5, 2029 Estimated
First posted
Feb 24, 2025 Actual
Last updated
Nov 10, 2026 Actual

Official study contacts

Waleed Ghanima, ProfessorCONTACTwaleed.ghanima@so-hf.no69860000 0047
Hans Joakim Myklebust-Hansen, Medical DoctorCONTACThans.joakim.hansen@so-hf.no97501765 0047
Official study title

Evaluating a New Diagnostic Strategy for Suspected DVT Consisting of Point of Care D-dimer, AI-based Prediction Model and Compression Ultrasound

A HUMAN NEXT STEP

Ask Wellness Clinical Research

Your message goes to WCR, including when this study is run by another organization. WCR may offer general guidance but may not operate this trial, have access to its team or be able to enroll you.

Please do not include medical records, diagnoses, medications, insurance numbers or other sensitive details. This form is for general questions, not urgent care.

Sending a question does not enroll you in a trial.

Source: ClinicalTrials.gov API v2. Information is submitted by sponsors and investigators. NLM does not approve the safety or science of all listed studies. Registry disclaimer.

Retrieved: Nov 12, 2026 · Last registry update: Nov 10, 2026